Department of Medical Oncology, Sichuan Cancer Hospital, Chengdu, China.
Department of General Internal Medicine, Sichuan Cancer Hospital, Chengdu, China.
Life Sci. 2017 Nov 1;188:87-95. doi: 10.1016/j.lfs.2017.08.018. Epub 2017 Sep 1.
Up-regulation or down-regulation of microRNAs (miRNAs) has been found in non-small cell lung cancer (NSCLC). However, the role and mechanism of regulation of miR-542-3p in NSCLC is still unclear. This study aimed at investigating the primary biological function of miR-542-3p and FTSJ2 in NSCLC tumorigenesis and the correlation of miR-542-3p and FTSJ2 in NSCLC.
Our present results showed that miR-542-3p was down-regulated in NSCLC tissues and cancer cells. Overexpression of miR-542-3p inhibited cell proliferation, cell migration, cell cycle, EMT process and tumor growth in vitro, and induced cell apoptosis by MTT assay, colony formation assay, transwell migration assay, flow cytometry assay, RT-qPCR assay, western blot experiment and vivo model assay; miR-542-3p directly bound to the 3'UTR of FTSJ2 and upregulated FTSJ2 both mRNA and protein level by EGFP reporter assay, RT-qPCR and western blot analysis in NSCLC cells. FTSJ2 also reduced the aggressiveness of NSCLC cells.
In short, miR-542-3p functions as a suppressor gene by targeting and upregulating FTSJ2, thus inhibiting the malignancy of NSCLC cells.
According to the results, miRNA-542-3p and its targeted FTSJ2 may be indispensable as a predictive biomarker of the response to the treatment in patients with NSCLC.
已发现微小 RNA(miRNA)在非小细胞肺癌(NSCLC)中的表达上调或下调。然而,miR-542-3p 在 NSCLC 中的作用和调节机制尚不清楚。本研究旨在探讨 miR-542-3p 和 FTSJ2 在 NSCLC 肿瘤发生中的主要生物学功能,以及 miR-542-3p 和 FTSJ2 在 NSCLC 中的相关性。
我们的研究结果表明,miR-542-3p 在 NSCLC 组织和癌细胞中下调。miR-542-3p 的过表达在体外抑制细胞增殖、细胞迁移、细胞周期、EMT 过程和肿瘤生长,并通过 MTT 测定、集落形成测定、Transwell 迁移测定、流式细胞术分析、RT-qPCR 测定、western blot 实验和体内模型测定诱导细胞凋亡;miR-542-3p 通过 EGFP 报告测定、RT-qPCR 和 western blot 分析,直接结合到 FTSJ2 的 3'UTR 上,上调了 NSCLC 细胞中 FTSJ2 的 mRNA 和蛋白水平。FTSJ2 也降低了 NSCLC 细胞的侵袭性。
总之,miR-542-3p 通过靶向和上调 FTSJ2 发挥抑癌基因的作用,从而抑制 NSCLC 细胞的恶性程度。
根据这些结果,miRNA-542-3p 及其靶向的 FTSJ2 可能是 NSCLC 患者治疗反应的预测生物标志物不可或缺的一部分。